The aim of the study was to develop colon targeted film coated tablets of Ornidazole using HPMC K₄M, HPMC K100 and Eudragit S100 as carriers. Ornidazole is used for the treatment of amoebiasis. The different approaches are designed based on prodrug formulation, pH-sensitivity, time-dependency (lag time), microbial degradation and osmotic pressure etc to formulate the different dosage forms like tablets, capsules, multiparticulates, microspheres, liposomes for colon targeting. The tablets are prepared by using compression method. The prepared tablets are evaluated in terms of their precompression studies, hardness test, thickness test, weight variation test, friability test, invitro study and stability studies. The results of the study showed that formulation FOT-3 is most likely to provide targeting of Ornidazole for local action in the colon.  The most satisfactory formulation was stable during stability studies conducted for 60 days as per ICH guidelines. It showed no significant changes in the physicochemical parameters and in vitro release of drug.

The use of herb to cure cancer takes a concrete breakthrough. It means that it is very essential to have a development on herb referring to a standar quality, efficacy andsafety. Therefore, we need an analysis against the mechanism of herb on molecular level.  Chlorogenic Acid (CA) is an active compound isolated from traditional plants from robusta coffee that is used as a chemopreventive therapy Hepatocellular Carcinoma(HCC), allegedly works as an anticancer and prevents the cell from destruction, also inhibits the growth of the cancer cells through the inhibition of free radicals. The research was done by in vitro, by using the Cell Lines Hep-G2 series 1886, obtained from Riken Cell Bank-Tohoku University.The aim of the research is how to understand the mechanism of CA in inhibiting HCCgrowth by using the model of Cell Lines Hep-G2 series 1886 through a series of gene expression. The type of research is experimental on 72 sample groups. 1 group consists of250 thousands cancer cells. The research uses 3 doses of CA: 727, 500 and 250 µM, with 3 times repeated measurement, and thencompared after and before the exposure. The role of those doses CAagainst Hep-G2 is analysed by comparing the expression of miRNA 146 A, before and after the exposure on 0, 8, 18 and 24 hours. The data is tested statistically with different test, t, repeated measurement, pearson and multiple linear regression.The lowest expression decrease of miRNA 146 A happened in the group 24 hours after the exposure at doses of 727 µM CA(0.85), followed by 500 µM (1.28) and the highest expression increase happened at a dose of 250 µM (1.61), continued with a statistical test at the 8^th and the 18^th hour Cq values miRNA 146 A significant difference p<0.05 at all doses CA (727,500 and 250 µM).The conclusion of the research is CAplays the important role on the reduction of miRNA 146 A expression.

An isocratic Simultaneous estimation by RP-HPLC Method was developed and validated for the quantification of Indapamide and Amlodipine Besylate in tablet dosage form. Quantification was achieved by  using the mobile phase (Phosphate buffer PH3: Acetonitrile: Methanol) in the ratio of 40:20:40. A C18 column contains octadecylsilane chemically bonded to porous silica particles was used as stationary phase. The flow rate was 1.0 ml/min. Measurements were made at a wavelength of 215nm. The average retention time for Indapamide and Amlodipine Besylate were found to be 2.07 min and 4.047. The proposed method was validated for selectivity, precision, linearity and accuracy. The assay methods were found to be linear from 9-21 µg/ml for Indapamide and 30-70 µg/ml for Amlodipine Besylate. All the validation parameters were found to be within the acceptable range. The developed method was successfully applied to estimate the amount of Indapamide and Amlodipine Besylate in tablet dosage form.

An isocratic Simultaneous estimation by RP-HPLC Method was developed and validated for the quantification of Indapamide and Nebivolol Hydrochloridein tablet dosage form. Quantification was achieved by using the mobile phase (Ammonium acetate buffer pH4.5: Methanol) in the ratio of 45:55. A Kromosil C18 column (250*4.6, 3.5µm) was used as stationary phase. The flow rate was 1.0 ml/min. Measurements were made at a wavelength of 226nm. The average retention time for Indapamide and Nebivolol Hydrochloridewere found to be 2.35 min and 3.49 min. The proposed method was validated for selectivity, precision, linearity and accuracy. The assay methods were found to be linear from 9-21 µg/ml for Indapamide and 30-70 µg/ml for Nebivolol Hydrochloride. All validation parameters were within the acceptable range. The developed methods were successfully applied to estimate the amount of Indapamide and Nebivolol Hydrochloridein tablet dosage form.

Mosquito-borne diseases are one of the major barriers preventing economic progress in the developing world. According to the World Health Organization, 200 million people were victims of malaria in 2010 and 655,000, mostly children, died from it. Dengue fever is believed to affect 50-100 million people per year and results in around 20,000 deaths. Dengue is the most important mosquito-borne, human viral disease in many tropical and sub-tropical areas. In Brazil the disease has been essentially described in the form of case series.Despite the presence of dengue in Brazil since the early 1981s, dengue has become a major public health issue, with a high morbidity and mortality. Aedes aegypti and Aedes albopictus are the vectors responsible for the transmission of dengue viruses (DENV). The genetically modified (GM) mosquitoes being used in these field experiments and cited alternative methods for dengue control. This technology and its impact to the environment studies have focused on controlling the mosquito populations by genetically modifying the insects. Tactics to protect people in endemic areas such as stopping mosquito bites using insecticides, net and repellents, developing preventive drugs and health education to manage mosquito-borne diseases have not shown fully effectiveness.